الإحصائيات الأساسية
| LEI | 549300LJKCS74GRYKF90 |
| CIK | 1593984 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MediWound Ltd.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 19, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 14, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 14, 2025 |
Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Unaudited Condensed Interim Consolidated Statements of Financial Position F-2 Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss F-3 Unaudited Condensed Interim Consolidat |
|
| August 14, 2025 |
Exhibit 99.1 MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Mi |
|
| May 21, 2025 |
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8 |
|
| May 21, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| May 15, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| April 7, 2025 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| April 7, 2025 |
Exhibit 99.2 MEDIWOUND LTD. PROXY FOR THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2025 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Yaron Meyer, Hani Luxenburg and/or Ofer Gonen, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of t |
|
| April 7, 2025 |
Exhibit 99.1 MEDIWOUND LTD. 42 Hayarkon Street, Yavne 8122745, Israel April 7, 2025 NOTICE OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2025 Dear MediWound Ltd. Shareholders: We cordially invite you to attend the 2025 annual general meeting of shareholders, or the Meeting, of MediWound Ltd., or the Company, to be held at 10:00 a.m. Eastern Daylight Time (EDT) on Thursday, M |
|
| March 28, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-285908 PROSPECTUS $125,000,000 of Ordinary Shares, Warrants and/or Debt Securities, Separately and/or Units, Offered by the Company. and Up to 1,266,141 Ordinary Shares Offered by the Selling Shareholder MediWound Ltd. We may offer from time to time in one or more series or issuances ordinary shares, warrants to purchase ordinary shares and/or |
|
| March 25, 2025 |
MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel +972 (77) 971-4100 MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel +972 (77) 971-4100 March 25, 2025 Via EDGAR Transmission Tim Buchmiller Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MediWound Ltd. Registration Statement on Form F-3 Filed March 19, 2025 Registration No. 333-285908 Dear Mr. Buchmiller: In accordance with Rule 461 of Regulati |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (Nos. 333-223767, 333-195517, 333-210375, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997) on Form S-8, and (Nos. 333-265203, 333-268297 and 333-281843) on Form F-3 of our report dated March 19, 2025, with respect to the consolidated financ |
|
| March 19, 2025 |
Exhibit 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MediWound Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ofer Gonen, do cert |
|
| March 19, 2025 |
MEDIWOUND LTD. INSIDER TRADING POLICY Exhibit 11.1 MEDIWOUND LTD. INSIDER TRADING POLICY This document sets forth the Insider Trading Policy (the “Policy”) of MediWound Ltd. and its subsidiaries (collectively, “MediWound”). The Policy establishes the policies and procedures that govern trading by MediWound personnel in MediWound securities and securities of any other company about which such personnel learns material, nonpublic inform |
|
| March 19, 2025 |
Exhibit 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MediWound Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Hani Luxenburg, do |
|
| March 19, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MEDIWOUND LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity O |
|
| March 19, 2025 |
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conferenc |
|
| March 19, 2025 |
Form of Indenture MEDIWOUND LTD. Dated as of ________, _____ TABLE OF CONTENTS Exhibit 4.1 Form of Indenture MEDIWOUND LTD. and INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Series 5 Section 2.02 Establishment of |
|
| March 19, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form F-3 (Form Type) MediWound Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration |
|
| March 19, 2025 |
Exhibit 4.9 Mediwound Ltd. 2024 Share Incentive Plan Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2024 Share Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Providers of Mediwound Ltd., an Israeli company (together with any successor |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025. As filed with the Securities and Exchange Commission on March 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIWOUND LTD. (Exact Name of Registrant as Specified in its charter) Israel (State or other jurisdiction of Incorporation or Organization) Not Applicable (I.R.S. Employ |
|
| March 19, 2025 |
Exhibit 12.2 CERTIFICATIONS I, Hani Luxenburg, certify that: 1. I have reviewed this annual report on Form 20-F of MediWound Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th |
|
| March 19, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check ma |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT |
|
| March 19, 2025 |
Exhibit 12.1 CERTIFICATIONS I, Ofer Gonen, certify that: 1. I have reviewed this annual report on Form 20-F of MediWound Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe |
|
| February 12, 2025 |
Exhibit 99.1 MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaborations with Solventum, Mölnlycke, and MIMED |
|
| February 12, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| February 11, 2025 |
EX-99.A BD-DIR-RESOL 2 exhajointfiling.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| January 8, 2025 |
Exhibit 99.1 January 2025 I Nasdaq: MDWD Next - Generation Enzymatic Therapeutics for Non - Surgical Tissue Repair 2 Cautionary Note Regarding Forward - Looking Statements This presentation contains “ forward - looking statements ” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial pote |
|
| January 8, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 26, 2024 |
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update Exhibit 99.1 MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Excee |
|
| November 26, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 14, 2024 |
Exhibit 99.1 MEDIWOUND LTD. 42 Hayarkon Street, Yavne 8122745, Israel November 14, 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 19, 2024 Dear MediWound Ltd. Shareholders: We cordially invite you to attend an extraordinary general meeting of shareholders, or the Meeting, of MediWound Ltd., or the Company, to be held at 10:00 a.m. Eastern Standard Time (EST) on |
|
| November 14, 2024 |
Exhibit 99.2 MEDIWOUND LTD. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 19, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Ofer Gonen, Hani Luxenburg and/or Yaron Meyer, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to ea |
|
| November 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 14, 2024 |
MDWD / MediWound Ltd. / Point72 Asset Management, L.P. - MEDIWOUND LTD. Passive Investment SC 13G/A 1 p24-3183sc13ga.htm MEDIWOUND LTD. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MediWound Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.07 per share (Title of Class of Securities) M68830112 (a) (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check th |
|
| October 23, 2024 |
MDWD / MediWound Ltd. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmdwd13ga4sep2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 04) Under the Securities Exchange Act of 1934 MEDIWOUND LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M68830104 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| October 23, 2024 |
EX-99.A BD-DIR-RESOL 2 exhajointfiling.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| October 1, 2024 |
MDWD / MediWound Ltd. / Yelin Lapidot Holdings Management Ltd. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* MediWound Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.07 per share (Title of Class of Securities) M68830112 (CUSIP Number) September 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| October 1, 2024 |
EX-99.1 2 ea021624201ex99-1medi.htm JOINT FILING AGREEMENT FILED BY AND AMONG THE REPORTING PERSONS, DATED AS OF OCTOBER 1, 2024 Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by ea |
|
| September 9, 2024 |
424B3 1 zk2432000.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-281843 PROSPECTUS MediWound Ltd. 1,453,488 Ordinary Shares This prospectus relates to the resale by the selling shareholders named in this prospectus (the “Selling Shareholders”) from time to time of up to 1,453,488 of our ordinary shares, par value NIS 0.07 per share. Our registration of the ordinary shares covered |
|
| September 5, 2024 |
MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel +972 (77) 971-4100 MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel +972 (77) 971-4100 September 5, 2024 Via EDGAR Transmission Tim Buchmiller Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MediWound Ltd. Registration Statement on Form F-3 Filed August 29, 2024 Registration No. 333-281843 Dear Mr. Buchmiller: In accordance with Rule 461 of Regu |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024 As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. |
|
| August 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) MediWound Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward |
|
| August 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 15, 2024 |
Exhibit 99.1 MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages YAVNE, Israel, August 15, 2024 - MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics |
|
| August 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 14, 2024 |
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update Exhibit 99.1 MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable Market; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke |
|
| August 14, 2024 |
Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Unaudited Condensed Interim Consolidated Statements of Financial Position F-2 Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss F-3 Unaudited Condensed Interim Consolidat |
|
| August 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 14, 2024 |
Exhibit 99.3 Operating and Financial Review and Prospects You should read the following discussion together with the unaudited consolidated financial statements as of and for the six months ended June 30, 2023 and 2024 and related notes appearing elsewhere in this Form 6-K, our audited consolidated financial statements and other financial information as of and for the year ended December 31, 2023 |
|
| August 14, 2024 |
August 2024 I Nasdaq: MDWD Next - Generation Enzymatic Therapeutics for Non - Surgical Tissue Repair Exhibit 99.1 August 2024 I Nasdaq: MDWD Next - Generation Enzymatic Therapeutics for Non - Surgical Tissue Repair 2 Cautionary Note Regarding Forward - Looking Statements This presentation contains “ forward - looking statements ” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial poten |
|
| August 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 5, 2024 |
Exhibit 99.1 MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients YAVNE, Israel, August 5, 2024 - MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the |
|
| July 19, 2024 |
MDWD / MediWound Ltd. / Access Industries Holdings LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* MediWound Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.07 per share M68830112 (Title of class of securities) (CUSIP number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10019 (212 |
|
| July 19, 2024 |
EX-99.1 2 ef20032647ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Ordinary Shares of MediWound Ltd. and further agree that this Joint Filin |
|
| July 19, 2024 |
MDWD / MediWound Ltd. / Molnlycke Health Care AB - SC 13D Activist Investment SC 13D 1 ef20032647sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* MediWound Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.07 per share (Title of Class of Securities) M68830112 (CUSIP Number) Kristin Hedlund Executive Vice President Legal Mölnlycke AB Gamlestadsvägen 3C, 415 1 |
|
| July 16, 2024 |
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program Exhibit 99.1 MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 - MediWound Ltd. (Nasdaq: MDWD), the global leader in next-genera |
|
| July 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 15, 2024 |
Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 15, 2024, between MediWound Ltd., an Israeli company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Share Purchase Agreement, dated a |
|
| July 15, 2024 |
Amendment No.2 to Settlement Agreement and Mutual General Release Exhibit 4.1 Amendment No.2 to Settlement Agreement and Mutual General Release This Amendment No.2 to Settlement Agreement and Mutual General Release (this “Second Amendment”) is made effective of July 15, 2024 (the “Effective Date”) by and between Teva Pharmaceutical Industries Ltd. ("Teva"), on the one hand, and MediWound Ltd. ("MediWound"), on the other hand. Teva and MediWound are together refe |
|
| July 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 15, 2024 |
Exhibit 4.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of July 15, 2024, between MediWound Ltd., an Israeli company (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i |
|
| July 15, 2024 |
COLLABORATION AND RIGHTS AGREEMENT Exhibit 4.3 COLLABORATION AND RIGHTS AGREEMENT THIS COLLABORATION AND RIGHTS AGREEMENT (this “Agreement”), is made as of July 15, 2024, by and between MediWound Ltd., an Israeli company (“MediWound”), and Molnlycke Health Care AB, a Swedish corporation (“Mölnlycke”). Each of MediWound and Mölnlycke shall be referred to herein as a “Party” and collectively as the “Parties”. WITNESSETH WHEREAS, Medi |
|
| July 15, 2024 |
Exhibit 99.1 MediWound Announces $25 Million Strategic Private Placement Financing Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 - MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share pu |
|
| July 11, 2024 |
MDWD / MediWound Ltd. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmdwd13ga3july.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 03) Under the Securities Exchange Act of 1934 MEDIWOUND LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M68830104 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| July 11, 2024 |
EX-99.A BD-DIR-RESOL 2 exhajointfiling.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| July 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| May 29, 2024 |
Exhibit 99.1 MEDIWOUND LTD. 42 Hayarkon Street, Yavne 8122745, Israel May 29, 2024 NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 9, 2024 Dear MediWound Ltd. Shareholders: We cordially invite you to attend the 2024 annual general meeting of shareholders, or the Meeting, of MediWound Ltd., or the Company, to be held at 10:00 a.m. Eastern Daylight Time (EDT) on Tuesday, Jul |
|
| May 29, 2024 |
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update Exhibit 99.1 MediWound Reports First Quarter 2024 Financial Results and Provides Company Update NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Isr |
|
| May 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| May 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| May 29, 2024 |
Exhibit 99.2 MEDIWOUND LTD. PROXY FOR THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 9, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Yaron Meyer, Hani Luxenburg and/or Ofer Gonen, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of t |
|
| April 25, 2024 |
EX-99.A BD-DIR-RESOL 2 exhajointfiling.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| April 25, 2024 |
MDWD / MediWound Ltd. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmdwd13ga2apr24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No: 02) Under the Securities Exchange Act of 1934 MEDIWOUND LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M68830104 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| March 21, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check ma |
|
| March 21, 2024 |
Consent of Independent Registered Public Accounting Firm EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (Nos. 333-223767, 333-195517, 333-210375, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997) on Form S-8, and (Nos. 333-265203 and 333-268297) on Form F-3 of our report dated March 21, 2024, with respect to the consolidated financial statemen |
|
| March 21, 2024 |
EXHIBIT 12.2 CERTIFICATIONS I, Hani Luxenburg, certify that: 1. I have reviewed this annual report on Form 20-F of MediWound Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th |
|
| March 21, 2024 |
MEDIWOUND LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 MEDIWOUND LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION MediWound Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy that are not otherwise defined herein shall have the respective meanings assigned thereto in Section 1 |
|
| March 21, 2024 |
Unprotected Lease Agreement Entered into and executed in Tel Aviv as of this 13th day of July 2023 Exhibit 4.14 This exhibit is an English translation of the original document in Hebrew. In case of any discrepancy, the Hebrew version prevails Unprotected Lease Agreement Entered into and executed in Tel Aviv as of this 13th day of July 2023 Between: YEZUM-TECH BUSINESS AND ASSETS LTD (Company Reg. No. 51-152477-9) Of 24 Shai Agnon St. (apt. 28), Tel Aviv (Hereinafter: the “Lessor”) The first par |
|
| March 21, 2024 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Our authorized share capital consists of 20,000,000 ordinary shares, par value NIS 0.07 per share, of which shares are issued and outstanding as of March 15, 2024. All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights. All ordinary shares have ident |
|
| March 21, 2024 |
EXHIBIT 12.1 CERTIFICATIONS I, Ofer Gonen, certify that: 1. I have reviewed this annual report on Form 20-F of MediWound Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT |
|
| March 21, 2024 |
EXHIBIT 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MediWound Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ofer Gonen, do cert |
|
| March 21, 2024 |
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update $19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid® commercially launched in U.S., Japan, India Potential blockbuster EscharEx® to begin Phase III in the second half of 2024 $42 million cash runway through profitability Conference call today, March 21 at 8:30am Ea |
|
| March 21, 2024 |
EXHIBIT 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MediWound Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Hani Luxenburg, do |
|
| March 21, 2024 |
TURNKEY PROJECT AGREEMENT This Agreement is made the 17 day of July 2023 Exhibit 4.23 TURNKEY PROJECT AGREEMENT This Agreement is made the 17 day of July 2023 BETWEEN Mediwound Ltd. registration number 512894940, a company incorporated in Israel and having its principal place of business at 42 Ha’Yarkon St., Yavne 8122745 Israel (the “Customer”) AND Biopharmax Group Ltd. registration number 51-241021-8, a private company incorporated in Israel and having its principal |
|
| March 21, 2024 |
Exhibit 1.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF MEDIWOUND LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759 – 1999 INTERPRETATION 1. 1.1. In these Articles, unless the context requires another meaning the words in the first column of the following table shall have the meanings set opposite them in the second column: “Alternate Nominee” as defined in Article 77.1; “Articles |
|
| February 14, 2024 |
EX-99.A BD-DIR-RESOL 2 exhajointfiling.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct |
|
| February 14, 2024 |
MDWD / MediWound Ltd. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindmdwd13ga1dec.htm SC 13G Mediwound13G.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 MEDIWOUND LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M68830104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the |
|
| February 12, 2024 |
Exhibit 99.2 February 2024 I Nasdaq: MDWD Next-Generation Enzymatic Therapeuticsfor Non-Surgical Tissue Repair ChronEx Phase II Study Data: A Head-to-Head Comparison of EscharEx® vs. SANTYL® 2 Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws, incl |
|
| February 12, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| February 12, 2024 |
Exhibit 99.1 MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU) YAVNE, |
|
| January 9, 2024 |
Exhibit 99.1 MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S. NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan YAVNE, Israel, Janu |
|
| January 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| January 8, 2024 |
MDWD / MediWound Ltd. / Deep Insight Limited Partnership - SC 13G/A Passive Investment SC 13G/A 1 zk2430753.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 MEDIWOUND LTD. (Name of Issuer) O |
|
| January 8, 2024 |
Exhibit 99.1 January 2024 I Nasdaq: MDWD Next-Generation Enzymatic Therapeuticsfor Non-Surgical Tissue Repair 2 Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of ou |
|
| January 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| January 8, 2024 |
MDWD / MediWound Ltd. / Israel Biotech Fund II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 zk2430751.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 MEDIWOUND LTD. (Name of Issuer) O |
|
| December 28, 2023 |
Exhibit 99.1 MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million YAVNE, Israel, December 28, 2023 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused |
|
| December 28, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 21, 2023 |
Exhibit 99.1 MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer YAVNE, Israel, November 21 2023 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief |
|
| November 21, 2023 |
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update Exhibit 99.1 MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Cash of $46 million; Operating cash runway through profitability Conf |
|
| November 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 13, 2023 |
Exhibit 99.1 MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients The label expansion will solidify NexoBrid’s position in the EU as a safe and effective non- surgical treatment for burn patients of all ages YAVNE, Israel, November 13, 2023 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on n |
|
| September 26, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by chec |
|
| September 26, 2023 |
Exhibit 99.1 MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution YAVNE, Israel, September 26, 2023 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic ther |
|
| September 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by chec |
|
| September 21, 2023 |
Exhibit 99.1 MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns YAVNE, Israel, September 21, 2023 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD), a f |
|
| September 1, 2023 |
EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended. Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person containe |
|
| September 1, 2023 |
MDWD / MediWound Ltd / Access Industries Holdings LLC - SC 13D/A Activist Investment SC 13D/A 1 d545622dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* MediWound Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.07 per share M68830112 (Title of class of securities) (CUSIP number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Stre |
|
| August 15, 2023 |
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update Exhibit 99.1 MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing not anticipated to impact revenues in 2023-2024 Cash of $51.3 million; operating cash runway through profita |
|
| August 15, 2023 |
Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Unaudited Condensed Interim Consolidated Statements of Financial Position F-2 Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss F-3 Unaudited Condensed Interim Consolidat |
|
| August 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 15, 2023 |
As filed with the Securities and Exchange Commission on August 15, 2023. As filed with the Securities and Exchange Commission on August 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIWOUND LTD. (Exact Name of Registrant as Specified in its charter) Israel (State or other jurisdiction of Incorporation or Organization) Not Applicable (I.R.S. Emplo |
|
| August 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 15, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MEDIWOUND LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity O |
|
| August 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| July 17, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 10, 2023 |
Exhibit 99.1 MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic |
|
| July 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 3, 2023 |
Exhibit 99.1 MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers YAVNE, Israel, July 3, 2023 (GLOBE NEWSWIRE) – MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic thera |
|
| May 31, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| May 31, 2023 |
Exhibit 99.1 May 2023 I Nasdaq: MDWD Next-Generation Enzymatic Therapeuticsfor Non-Surgical Tissue Repair 2 Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our pr |
|
| May 31, 2023 |
6-K 1 zk2329832.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices |
|
| May 30, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| May 30, 2023 |
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update Exhibit 99.1 MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update On track to initiate EscharEx® Phase III study in fourth quarter 2023 NexoBrid® U.S. launch expected in early third quarter 2023 Cash of over $57 million; Operating cash runway through profitability Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, May 30, 2022 - MediWound Ltd. (Na |
|
| May 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark |
|
| May 9, 2023 |
Exhibit 99.1 MediWound Announces an Additional $10 Million Award from BARDA Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension YAVNE, Israel, May 9, 2023 - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announ |
|
| April 20, 2023 |
Exhibit 99.1 MEDIWOUND LTD. 42 Hayarkon Street, Yavne 8122745, Israel April 20, 2023 NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 31, 2023 Dear MediWound Ltd. Shareholders: We cordially invite you to attend the 2023 annual general meeting of shareholders, or the Meeting, of MediWound Ltd., or the Company, to be held at 10:00 a.m. Eastern Daylight Time (EDT) on Wednesday, |
|
| April 20, 2023 |
Exhibit 99.2 MEDIWOUND LTD. PROXY FOR THE 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 31, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Yaron Meyer and/or Hani Luxenburg and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to repre |
|
| April 20, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check ma |
|
| April 6, 2023 |
MediWound Ltd. 4,021,880 Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333- 268297 PROSPECTUS MediWound Ltd. 4,021,880 Ordinary Shares This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to 4,021,880 of our ordinary shares, par value NIS 0.07 per share. All numbers in this prospectus reflect the 1-for-7 reverse stock split that went into effect on December |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| March 31, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 Form Type MediWound Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Fees to be Paid — |
|
| March 16, 2023 |
6-K 1 zk2329390.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offic |
|
| March 16, 2023 |
EXHIBIT 12.2 CERTIFICATIONS I, Boaz Gur-Lavie, certify that: 1. I have reviewed this annual report on Form 20-F of MediWound Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to th |
|
| March 16, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check ma |
|
| March 16, 2023 |
As Filed with the Securities and Exchange Commission on March 16, 2023 As Filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
EXHIBIT 13.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MediWound Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Boaz Gur-Lavie, do |
|
| March 16, 2023 |
MediWound Ltd. 28,153,058 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-268297 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated November 25, 2022) MediWound Ltd. 28,153,058 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of November 25, 2022 (as supplemented or amended from time to time, the “Prospectus”) (Regist |
|
| March 16, 2023 |
EXHIBIT 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MediWound Ltd. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ofer Gonen, do cert |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT |
|
| March 16, 2023 |
Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update 2022 total revenues of $26.5 million FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second quarter of 2023 EscharEx® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023 Cash position of $66 million, includ |
|
| March 16, 2023 |
EXHIBIT 12.1 CERTIFICATIONS I, Ofer Gonen, certify that: 1. I have reviewed this annual report on Form 20-F of MediWound Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the pe |
|
| March 16, 2023 |
MediWound Ltd. 28,153,058 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-268297 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated November 25, 2022) MediWound Ltd. 28,153,058 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of November 25, 2022 (as supplemented or amended from time to time, the “Prospectus”) (Regist |
|
| March 16, 2023 |
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer Exhibit 99.1 MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer Yavne, Israel, March 16, 2023 (GLOBE NEWSWIRE) – MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial |
|
| March 16, 2023 |
EXHIBIT 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No.’s 333-223767, 333-195517, 333-210375, 333-230487, 333-236635, 333-255784, and 333-266697) on Form S-8, in the registration statement (No. 333-265203) on Form F-3 and in the registration statement (No. 333-268297) on form F-1, of our report dated Marc |
|
| March 16, 2023 |
Amended and Restated Articles of Association of the Registrant, as amended EXHIBIT 1.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF MEDIWOUND LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759 – 1999 INTERPRETATION 1. 1.1. In these Articles, unless the context requires another meaning the words in the first column of the following table shall have the meanings set opposite them in the second column: “Alternate Nominee” as defined in Article 77.1; “Articles |
|
| March 16, 2023 |
EXHIBIT 2.1 DESCRIPTION OF SECURITIES Our authorized share capital consists of 50,000,000 ordinary shares, par value NIS 0.07 per share, of which 12,857,143 shares are issued and outstanding as of March 15, 2023. All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights. All ordinary shares |
|
| March 16, 2023 |
EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No.’s 333-223767, 333-195517, 333-210375, 333-230487, 333-236635 and 333-266697) on Form S-8, in the registration statement (No. 333-265203) on Form F-3 and in the registration statement (No. 333-268297) on form F-1, of our report dated March 17, 2022, w |
|
| February 14, 2023 |
MDWD / Mediwound Ltd / ROSENBERG LIOR - SC 13G/A Passive Investment SC 13G/A 1 zk2329247.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* MediWound Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.07 per share (Title of Class of Securities) M68830112 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 13, 2023 |
MDWD / Mediwound Ltd / Access Industries Holdings LLC - SC 13D/A Activist Investment SC 13D/A 1 d360484dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* MediWound Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.07 per share M68830112 (Title of class of securities) (CUSIP number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor |
|
| February 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| February 13, 2023 |
EX-99.2 3 d360484dex992.htm EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is respons |
|
| February 13, 2023 |
MEDIWOUND LTD. PIGGY-BACK RIGHTS WAIVER EX-99.1 2 d360484dex991.htm EX-99.1 Exhibit 99.1 MEDIWOUND LTD. PIGGY-BACK RIGHTS WAIVER Reference is made to the Amended & Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”), dated as of April 6, 2021, by and among MediWound Ltd. (the “Company”) and the shareholders of the Company listed on Schedule A thereto (the “Shareholders”). All capitalized terms used herein an |
|
| February 8, 2023 |
EX-99.1 2 pt7213gb.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf |
|
| February 8, 2023 |
MDWD / Mediwound Ltd / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 pt7213ga.htm SCHEDULE 13G 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) MediWound Ltd. (Title of Class of Securities) Ordin |
|
| February 7, 2023 |
Re: Offering of Ordinary Shares Via Prospectus Supplement Exhibit 5.1 February 7, 2023 To: MediWound Ltd. 42 Hayarkon Street Yavne, 8122745 Israel Re: Offering of Ordinary Shares Via Prospectus Supplement Ladies and Gentlemen: We have acted as Israeli counsel for MediWound Ltd., an Israeli company (the “Company”), in connection with the offer, issuance and sale (collectively, the “Offering”) by the Company of 1,964,286 ordinary shares, par value NIS 0.07 |
|
| February 7, 2023 |
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares EX-99.2 5 exhibit99-2.htm EXHIBIT 99.2 Exhibit 99.2 MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, February 7, 2023 - MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced reg |
|
| February 7, 2023 |
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market Exhibit 99.1 MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market YAVNE, Israel, February 3, 2023 - MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchas |
|
| February 7, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| February 7, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This securities purchase agreement (this “Agreement”) is dated as of February 3, 2023, between MediWound Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages attached hereto (each, including its successors and assignees, a “Purchaser” and collectively the “Purchasers”). WHERE |
|
| February 3, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-265203 PROSPECTUS SUPPLEMENT (To Prospectus dated June 3, 2022) 1,964,286 Ordinary Shares MediWound Ltd. We are offering to certain institutional and accredited investors 1,964,286 ordinary shares (“ordinary shares”) in this offering through this prospectus supplement and the accompanying prospectus. On February 3, 2023, the aggregate market va |
|
| January 9, 2023 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 January 2023 I Nasdaq: MDWD Non-Surgical Biological Solutions for Tissue Repair & Regeneration 2 Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements rela |
|
| January 9, 2023 |
6-K 1 zk2328981.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive off |
|
| January 9, 2023 |
MediWound Ltd. 28,153,058 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-268297 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated November 25, 2022) MediWound Ltd. 28,153,058 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of November 25, 2022 (as supplemented or amended from time to time, the “Prospectus”) (Regist |
|
| January 6, 2023 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-268297 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated November 25, 2022) MediWound Ltd. 28,153,058 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of November 25, 2022 (as supplemented or amended from time to time, the ?Prospectus?) (Regist |
|
| December 29, 2022 |
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults Exhibit 99.1 MediWound Announces FDA Approval of NexoBrid? for the Treatment of Severe Thermal Burns in Adults Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2 |
|
| December 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 23, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 23, 2022 |
Exhibit 99.1 MediWound Expands NexoBrid?s Global Presence with Marketing Approval in Japan Japan is the first country in the world to approve NexoBrid for people of all ages; pediatric and adult populations Exclusive marketing and distribution agreement with Kaken Pharmaceutical Co., Ltd. YAVNE, Israel, December 23, 2022 - MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company |
|
| December 21, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Mediwound Ltd. |
|
| December 21, 2022 |
MDWD / Mediwound Ltd / Rosalind Advisors, Inc. - MEDIWOUND SC 13 G Passive Investment SC 13G Mediwound13G.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MEDIWOUND LTD. (Name of Issuer) Common Shares (Title of Class of Securities) M68830104 (CUSIP Number) December 2, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| December 20, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 19, 2022 |
Exhibit 99.1 MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE, Israel, December 19, 2022 - MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company, focused o |
|
| December 19, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 5, 2022 |
Joint Filing Agreement, dated December 5, 2022 Exhibit 1.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto), and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the un |
|
| December 5, 2022 |
MDWD / Mediwound Ltd / Deep Insight Limited Partnership - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 MEDIWOUND LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 pe |
|
| December 5, 2022 |
MediWound Announces a 1-for-7 Reverse Share Split Exhibit 99.1 MediWound Announces a 1-for-7 Reverse Share Split YAVNE, Israel, December 5, 2022 - MediWound Ltd. (Nasdaq: MDWD) (?MediWound? or the ?Company?), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to effect a 1-for-7 reverse share split of its ordinary shares. Subject to t |
|
| December 5, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| December 5, 2022 |
Exhibit 1.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto), and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. In evidence thereof, each of the un |
|
| December 5, 2022 |
MDWD / Mediwound Ltd / Israel Biotech Fund II, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 MEDIWOUND LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 pe |
|
| November 28, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 25, 2022 |
MediWound Ltd. 28,153,058 Ordinary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333- 268297 PROSPECTUS MediWound Ltd. 28,153,058 Ordinary Shares This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to 28,153,058 of our ordinary shares, par value NIS 0.01 per share. These 28,153,058 ordinary shares consist of: ? 9,853,058 ordinary shares (the ?Pre-Funded Warrant Shar |
|
| November 22, 2022 |
MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel November 22, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Attention: Joshua Gorsky Re: MediWound Ltd. Registration Statement on Form F-1 Filed November 10, 2022 File No. 333-268297 (the ?Registration Statement?) Request |
|
| November 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check |
|
| November 15, 2022 |
Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Unaudited Condensed Interim Consolidated Statements of Financial Position F-2 Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss F-3 Unaudited Condensed Interim Conso |
|
| November 15, 2022 |
MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update Exhibit 99.1 MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update $30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023 Co |
|
| November 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices |
|
| November 10, 2022 |
As Filed with the Securities and Exchange Commission on November 10, 2022 As Filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 Form Type MediWound Ltd. (Exact Name of Registrant as Specified in its Charter Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Fees to be Paid Eq |
|
| November 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by chec |
|
| November 9, 2022 |
Exhibit 99.1 MEDIWOUND LTD. AND ITS SUBSIDIARIES UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Unaudited Condensed Interim Consolidated Statements of Financial Position F-2 Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss F-3 Unaudited Condensed Interim |
|
| November 9, 2022 |
Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS A. Operating Results The information contained in this section should be read in conjunction with our unaudited condensed interim consolidated financial statements for the year ended June 30, 2022 and related notes, and the information contained elsewhere in this Report of Foreign Private Issuer on Form 6-K, our audited consolidated financi |
|
| October 21, 2022 |
Exhibit 99.1 MEDIWOUND LTD. 42 Hayarkon Street, Yavne 8122745, Israel October 21, 2022 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 28, 2022 Dear MediWound Ltd. Shareholders: We cordially invite you to attend an extraordinary general meeting of shareholders, or the Meeting, of MediWound Ltd., or the Company, to be held at 10:00 a.m. (Eastern Standard Time, or EST) |
|
| October 21, 2022 |
Exhibit 99.2 MEDIWOUND LTD. PROXY FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 28, 2022 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Stephen T. Wills, Ofer Gonen, Boaz Gur-Lavie and Adv. Tamar Fishman Jutkowitz, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full |
|
| October 21, 2022 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| September 26, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by chec |
|
| September 26, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This securities purchase agreement (this ?Agreement?) is dated as of September 22, 2022, between MediWound Ltd., a company organized under the laws of the State of Israel (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assignees, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, sub |
|
| September 26, 2022 |
MEDIWOUND LTD. PIGGY-BACK RIGHTS WAIVER Exhibit 99.1 MEDIWOUND LTD. PIGGY-BACK RIGHTS WAIVER Reference is made to the Amended & Restated Registration Rights Agreement (the ?A&R Registration Rights Agreement?), dated as of April 6, 2021, by and among MediWound Ltd. (the ?Company?) and the shareholders of the Company listed on Schedule A thereto (the ?Shareholders?). All capitalized terms used herein and not otherwise defined shall have t |
|
| September 26, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of [], 2022, by and between MediWound Ltd., a company organized under the laws of the State of Israel (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuan |
|
| September 26, 2022 |
MDWD / Mediwound Ltd / Access Industries Holdings LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* MediWound Ltd. (Name of Issuer) Ordinary Shares, Per Value NIS 0.01 per share M68830104 (Title of class of securities) (CUSIP number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10019 (212 |
|
| September 26, 2022 |
Exhibit 99.2 September 21, 2022 To: MediWound Ltd. Re: Company Shareholder Support Agreement Ladies and Gentlemen: This letter agreement (this ?Agreement?) is being delivered to MediWound Ltd., a company organized under the laws of the State of Israel (the ?Company?) in connection with that certain Securities Purchase Agreement, dated as of the date hereof, by and among the Company and the investo |
|
| September 26, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This securities purchase agreement (this ?Agreement?) is dated as of September 22, 2022, between MediWound Ltd., a company organized under the laws of the State of Israel (the ?Company?), and each purchaser identified on the signature pages attached hereto (each, including its successors and assignees, a ?Purchaser? and collectively the ?Purchasers?). WHE |
|
| September 26, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 26, 2022 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 26, 2022 |
Exhibit 99.1 MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million YAVNE, Israel, September 22, 2022 - MediWound Ltd. (NASDAQ: MDWD) (the ?Company?), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into |
|
| September 26, 2022 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 26, 2022 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 26, 2022 |
Exhibit 99.3 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accurac |
|
| September 22, 2022 |
7,575,513 Ordinary Shares MediWound Ltd. Filed Pursuant to Rule 424(b)(5) Registration No. 333-265203 PROSPECTUS SUPPLEMENT (To Prospectus dated June 3, 2022) 7,575,513 Ordinary Shares MediWound Ltd. We are offering to certain institutional and accredited investors 7,575,513 ordinary shares (?ordinary shares?) in this offering through this prospectus supplement and the accompanying prospectus. In a concurrent private placement to the sam |
|
| September 20, 2022 |
Exhibit 99.1 EMA Accepts MediWound?s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burns YAVNE, Israel, September 20, 2022 - MediWound Ltd. (NASDAQ: MDWD) (the ?Company?), a fully integrated biopharmaceutical company fo |
|
| September 20, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by chec |
|
| August 9, 2022 |
Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 IN U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Interim Consolidated Statements of Financial Position F-2 Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss F-3 Condensed Interim Consolidated Statements of Changes in Sh |
|
| August 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 9, 2022 |
As filed with the Securities and Exchange Commission on August 9 2022. As filed with the Securities and Exchange Commission on August 9 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIWOUND LTD. (Exact Name of Registrant as Specified in its charter) ISRAEL (State or other jurisdiction of Incorporation or Organization) Not Applicable (I.R.S. Employe |
|
| August 9, 2022 |
MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates Exhibit 99.1 MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership Team Conference Call Begins Today at 8:30 AM Eastern Time YAVNE, Israel, August 9, 2022 - MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmac |
|
| August 9, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MEDIWOUND LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity O |
|
| August 8, 2022 |
MediWound Enhances Its Board and Executive Leadership Team Exhibit 99.1 MediWound Enhances Its Board and Executive Leadership Team Mr. Nachum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer Yavne, Israel, August 8, 2022 - MediWound Ltd. (Nasdaq: MDWD) (the ?Company?), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today anno |
|
| August 8, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 3, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant’s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check m |
|
| August 3, 2022 |
Exhibit 99.1 MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023 YAVNE, Israel, August 3, 2022 - MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repa |
|
| July 19, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 12, 2022 |
Exhibit 99.1 Market Landscape Analysis & EscharEx Market PotentialKevin FengOliver Wyman In-depth interviews (N=30) with KOLs, community practitioners, payers in US / EU Current & future treatment dynamics Feedback on EscharEx profile and positioning Pharmacoeconomic considerations Web survey (N=200) fielded to quantify the opportunity for modeling (e.g. eligibility rate, tx rate, shares, etc.) In |
|
| July 11, 2022 |
Exhibit 99.1 MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 - MediWound Ltd. (Nasdaq: MDWD) (the ?Company?), a fully-integrated biopharmaceutical company focused on next-generati |
|
| July 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 7, 2022 |
Exhibit 99.1 MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUs Data Demonstrates EscharEx Reduced Wound Size, Biofilm and Bacterial Burden YAVNE, Israel, July 7, 2022 - MediWound Ltd. (Nasdaq: MDWD) (the ?Company?), a fully-integrated biopharmaceutical |
|
| July 7, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| July 1, 2022 |
Exhibit 99.5 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accurac |
|
| July 1, 2022 |
MDWD / Mediwound Ltd / Access Industries Holdings LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* MediWound Ltd. (Name of Issuer) Ordinary Shares, Per Value NIS 0.01 per share (Title of class of securities) M68830104 (CUSIP number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10019 (212 |
|
| June 30, 2022 |
Exhibit 99.1 MediWound Names Mr. Tzvi Palash as Chief Operating Officer Brings Extensive Operational Experience from International Pharmaceutical Companies YAVNE, Israel, June 30, 2022 - MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Mr. Tzvi Palas |
|
| June 30, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| June 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant?s name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mar |
|
| June 9, 2022 |
Exhibit 99.1 MEDIWOUND LTD. 42 Hayarkon Street, Yavne 8122745, Israel June 9, 2022 NOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 19, 2022 Dear MediWound Ltd. Shareholders: We cordially invite you to attend the 2022 annual general meeting of shareholders, or the Meeting, of MediWound Ltd., or the Company, to be held at 10:00 a.m. Eastern Daylight Time (EDT) on Tuesday, Ju |
|
| June 9, 2022 |
Exhibit 99.2 MEDIWOUND LTD. PROXY FOR THE 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 19, 2022 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Yaron Meyer and/or Boaz Gur-Lavie and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to repr |
|
| June 1, 2022 |
MediWound Ltd. 42 Hayarkon Street Yavne 8122745, Israel +972 (77) 971-4100 June 1, 2022 Via EDGAR Transmission Michael Davis Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: MediWound Ltd. Registration Statement on Form F-3 Filed May 25, 2022 Registration No. 333-265203 Dear Mr. Davis: In accordance with Rule 461 of Regulation C of th |
|
| May 25, 2022 |
As filed with the Securities and Exchange Commission on May 25, 2022 As filed with the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) MediWound Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration F |
|
| May 25, 2022 |
Form of Indenture relating to debt securities Exhibit 4.1 Form of Indenture MEDIWOUND LTD. and INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Series 5 Section 2.02 Establishment of |
